The courses were led by the EVI and designed to strengthen capacity in vaccine research and development (R&D), with a particular focus on supporting professionals from low- and middle-income countries (LMICs).

World Malaria Day is observed every year on 25 April to recognise global efforts to control malaria.

The OPT-MVAC consortium will support the rollout of malaria vaccines in 14 Central and West African countries.

An inactivated Hepatitis C vaccine showing promising results in preclinical trials moves closer to human trials, with a new project to establish and optimise production and manufacture of the vaccine.

New EVI-led project will assess the impact of enhancing seasonal malaria vaccination in Guinea and Benin. The findings could shape future...

EVI launched Phase II clinical trial to evaluate the R21/Matrix-M malaria vaccine (by Univ. of Oxford), in women of childbearing potential.

March 24 marks World Tuberculosis Day on the anniversary of Dr. Robert Koch's groundbreaking discovery of Mycobacterium tuberculosis in 1882

From establishing a strong clinical trial network to accelerating vaccine research and fostering cross-border collaboration, VACCELERATE...

A newly published article outlines the protocol for new phase Ia/b clinical trial for the Invaplex AR-Detox  Shigella vaccine...

The European vaccine development ecosystem has been strengthened over the last 16 years, thanks to the TRANSVAC project, funded by the EC.

Phase 1 clinical trials in the UK and Burkina Faso showed that the malaria vaccine candidate, R21 adjuvanted with Matrix-M, has an...

Neglected Tropical Diseases (NTDs) cause immense suffering and affect an estimated 1 billion people mostly in isolated and marginalised...

At the World Vaccine Congress 2024, an EVI-organised panel discussion explored the lessons learnt from licensed malaria vaccines.

Understanding cultural beliefs and practices around pregnancy and vaccination Our ethnographic study in Malawi—focused on understanding...

November 2024 Last week, the EVI team gathered in Frankfurt for a retreat designed to recharge, step away from our daily routines, and...

T he European Vaccine Initiative (EVI) proudly participated in the Product Development Partnerships (PDP) IV Annual Meeting on November...

AMR is growing on a global scale and has become a top 10 health threat that affects the effectiveness of antimicrobial medicines.

Two PhD students, Dr. Elizabeth Kibwana and Dr. Caroline Bundi, have successfully defended their dissertations under the Multi-Stage...

The phase Ia/b trial for the InvaplexAR-Detox/dmLT vaccine started at LUMC, in Netherlands.

European Vaccine Initiative (EVI) and the Tuberculosis Vaccine Initiative (TBVI) are proud to announce a new partnership with VAC4EU.

Collaboration will support Controlled Human Infection Model studies to accelerate development of effective and affordable RSV vaccines.

AMR Accelerator asks for long-term investments, emphasising the need to preserve the European capacity to combat drug-resistant infections.

EVI is thrilled to announce the launch of TRANSVAC Academy, a programme providing advanced expert-led training in vaccinology.

The European Pharmacopoeia has announced the end of the rabbit pyrogen testing.